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Chlamydophila pneumoniae is an intracellular pathogen responsible for a number of diﬀerent acute and chronic infections. The
recent deepening of knowledge on the biology and the use of increasingly more sensitive and speciﬁc molecular techniques has
allowed demonstration of C. pneumoniae in a large number of persons suﬀering from diﬀerent diseases including cardiovascular
(atherosclerosis and stroke) and central nervous system (CNS) disorders. Despite this, many important issues remain unanswered
with regard to the role that C. pneumoniae may play in initiating atheroma or in the progression of the disease. A growing body of
evidence concerns the involvement of this pathogen in chronic neurological disorders and particularly in Alzheimer’s disease
(AD) and Multiple Sclerosis (MS). Monocytes may traﬃc C. pneumoniae across the blood-brain-barrier, shed the organism
in the CNS and induce neuroinﬂammation. The demonstration of C. pneumoniae by histopathological, molecular and culture
techniques in the late-onset AD dementia has suggested a relationship between CNS infection with C. pneumoniae and the AD
neuropathogenesis. In particular subsets of MS patients, C. pneumoniae could induce a chronic persistent brain infection acting
as a cofactor in the development of the disease. The role of Chlamydia in the pathogenesis of mental or neurobehavioral disorders
including schizophrenia and autism is uncertain and fragmentary and will require further conﬁrmation.
1.IntroductionandBackground
Chlamydiae were taxonomically categorised into their own
order Chlamydiales, with one family, Chlamydiaceae,a n d
a single genus, Chlamydia which included four species: C.
trachomatis, C. pneumoniae, C. psittaci,a n dC. pecorum.
Two of the species, C. trachomatis and C. pneumoniae,a r e
common pathogens in humans, but the routes of trans-
mission, susceptible populations, and clinical presentations
diﬀer markedly. The other species occur mainly in animals
although C. psittaci may be also implicated in human
respiratory diseases. In 1999, a new taxonomic classiﬁcation
was proposed, renaming Chlamydia pneumoniae as Chlamy-
dophilapneumoniae[1].However,theproposaltochangethe
taxonomic nomenclature for the Chlamyadiaceae family has
not been universally accepted and both names are currently
in use by diﬀerent authors.
C. pneumoniae, a common cause of human respiratory
disease, was ﬁrst isolated from the conjunctiva of a child
in Taiwan in 1965 but it was not until the early 1980s
that it was scientiﬁcally identiﬁed as a distinct Chlamydia
species and was established as a major respiratory pathogen
in 1983 when it was isolated from the throat of a college
student at the University of Washington. Most likely, C.
pneumoniae is primarily transmitted from human to human
by the respiratory tract without any animal reservoir [2,
3] and infection spreads slowly. The incubation period is
several weeks, which is longer than that for many other2 Interdisciplinary Perspectives on Infectious Diseases
respiratory pathogens [4]. The time span of infection
spread in families is shorter, however, ranging from 5 to
18 days [5]. As other Chlamydia species, C. pneumoniae
has a unique biphasic life cycle with two forms that are
functionally and morphologically distinct that undergo an
orderlyalternation:theelementarybody(EB),infectiousand
metabolically inactive responsible for attaching to the target
host cell and promoting its entry and the reticulate body
(RB), an abortive non-infectious and metabolically active
intracellular form which replicates by binary ﬁssion and
reorganizes into EBs then released by cell lysis. In general,
it is likely that this aberrant developmental step leads to the
persistence of viable but non cultivable Chlamydiae within
infectedcellsoverlongperiods.Incellcultureconditions,the
duration of the developmental cycle is between 2 and 3 days,
depending on the strain, when bacteria have diﬀerentiated
back to EBs and are released in the extracellular medium. In
naturalinfections,the situationis more complicated,andthe
normal development of Chlamydia is easily disturbed. Living
separated from the host cell cytoplasm within its Chlamydial
inclusion (a nonlysosomal vacuole), C. pneumoniae is able
to create an intracellular niche from where it promotes
host cell survival or death, modulates regulatory host cell
signalling pathways, and bypasses the host cell’s defence
mechanisms. Thus, C. pneumoniae can induce a persistent
infection due to the inability of the host to completely
eliminate the pathogen [6–8]. The failure by the guest
to eradicate the disease involves the establishment of a
state of chronic infection in which C. pneumoniae after
internalization into mononuclear cells, enters into a state
of quiescence with intermittent periods of replication and
characterized by antigenic variation, production of Heat
Shock Proteins (HsPs) and proinﬂammatory cytokines capa-
ble of evading host defences and trigger tissue damage [8].
Chronic infection and clinical persistence are closely related.
In chronic infections a diﬀerent pathway is taken. Under
pressure from host defences the metabolic processes of the
organismarediminished.C.pneumoniaeinthisstateiscalled
the Cryptic Body (CB). This chronic unresolved infection,
whichcanlastforseveraldecades,canalsoinitiatethemalign
process of autoimmunity. To a large extent, the form of
the disease may depend on the host’s genetic inheritance.
This is why many of the chronic disease forms caused
by infections with C. pneumoniae tend to have inherited
characteristics. It is thought that the host immunity together
withindividualtraditionalriskfactors,serologicalmarkersof
C. pneumoniae infection and genetic susceptibility, may play
an important role in controlling Chlamydial infections. A
chronic C. pneumoniae infection increases the expression of
its own 60kDa heat shock proteins (HsP60), especially when
they are persistently elevated. The host immune response
to microbial HsP60 may gradually lead or, contribute to
autoimmunity to human HsP60 and, consequently, to the
development of some chronic diseases such as asthma
[9] atherosclerosis or clinical manifestations of Coronary
Hearth Disease (CHD) [4, 9–14]. Deﬁnitive pathogenesis
and virulence investigations for the Chlamydiae have been
hampered because methods for gene transfer have not
yet been developed for these microorganisms. Despite this
critical experimental limitation, a great deal of information
has been generated on intracellular Chlamydial growth and
development,andtheeﬀectsofchlamydialinfectiononhost-
cell physiology [15]. Like most intracellular pathogens, C.
pneumoniae interferes with the normal apoptotic signalling
pathways of these cells, perhaps contributing to long-term
persistenceandchronicinﬂammationincentralnervoussys-
tem (CNS) system. However, it is not clear how this happens:
under some circumstances these microorganisms induce
apoptosis and/or necrosis, but under other circumstances
they inhibit apoptosis [15, 16]. The circumstances that
dictate whether the Chlamydiae inhibit or activate host-cell
death reﬂect several important pathogenic considerations,
includingwhetheranacuteorchronicinfectionisinprogress
and whether intracellular chlamydial growth is programmed
togothrough aproductive infectious cycleoris stalledunder
non-productive growth conditions [16]. The intracellular
growth cycle of the Chlamydiae is complex and several
growthoptions are possible, depending on thehost-cell type,
the particular environmental conditions in the host cell and
the nature of the tissue that is being aﬀected. It is possible
that apoptotic activity is controlled to some extent by the
intracellular growth status of the Chlamydiae, which can be
inﬂuenced by any or all of these considerations [16].
Data on the distribution of seroprevalence reveal that
the prevalence of C. pneumoniae infection increases with
age. Antibodies against C. pneumoniae begin to appear at
school age but are rare in children under the age of 5, except
in developing and tropical countries. Antibody prevalence
increases rapidly at ages 5 to 14, reaches 50% at the age
of 20, and continues to increase slowly to 70% to 80% at
ages 60 to 70 [4]. This seems to suggest that most people
are infected and re-infected for life. C. pneumoniae accounts
for 6%–20% of community acquired pneumoniae (CAP) in
adults [3, 4], but participates in co-infection involving other
bacterial agents in approximately 30% of adult cases of CAP
[4]. Some studies have suggested a possible association of
C. pneumoniae infection and acute exacerbations of asthma
and chronic obstructive pulmonary diseases (COPD). In
recent years, however, in addition to respiratory diseases,
an increasing number of publications have been reported
of detection of C. pneumoniae in chronic extra-respiratory
diseases. In fact, the recent deepening of knowledge on
the biology of Chlamydia and the use of increasingly more
sensitive and speciﬁc molecular techniques, have allowed
to demonstrate the presence of C. pneumoniae DNA in a
large number of persons suﬀering from diﬀerent diseases
other than cardiovascular (atherosclerosis and stroke), such
as osteoarthritis and CNS disorders. In this setting, the
ability of C. pneumoniae to infect various human cells such
as epithelial, endothelial, and smooth muscle cells as well
as macrophages, monocytes, and lymphocytes, suggests a
systemic dissemination following exposure to a respiratory
infection. Certainly, the presence of C. pneumoniae DNA
in peripheral blood mononuclear cells (PBMCs) strongly
suggests that such dissemination can occur in a number
of diﬀerent tissues [17]. C. pneumoniae infection has been
shown to promote the transmigration of monocytes through
human brain endothelial cells, suggesting a mechanism byInterdisciplinary Perspectives on Infectious Diseases 3
whichtheorganismmayentertheCNS.Thismayaccountfor
the delivery of the organism to the CNS and result in chronic
injury [18].
This review addresses the potential and the underlying
mechanisms by which C. pneumoniae infections can play
ar o l ei nd i ﬀerent neurological diseases, examining the
epidemiological and methodological ﬁndings among studies
which will be highlighted. Suggestions for future studies
and potential standardization of tools and protocols are
proposed.
2.C. pneumoniae Infection, Atherosclerosis,
andCerebrovascularDiseases
2.1. C. pneumoniae and Atherosclerosis. If large is the
amount of data that support the role of C. pneumoniae
in the atherosclerosis, equally important is the weight that
C. pneumoniae has recently taken in the cerebrovascular
diseases. The mechanism of atherosclerotic disease and
thrombosis is not completely known. The ﬁrst report
of an association between C. pneumoniae infection and
atherosclerosis was by Saikku et al. [2]. Individuals with
immunoglobulin G antibody speciﬁc for C. pneumoniae
were shown to be at an increased risk for myocardial
infarction and CHD, as there was a statistically signiﬁcant
diﬀerence in the frequency of antibody in patients versus
controls. Subsequently, many other reports concerning the
seroepidemiological association between speciﬁc antibodies
to C. pneumoniae and atherosclerosis at several arterial
sites using retrospective, cross-sectional and prospective
studies, have conﬁrmed a link between C. pneumoniae
and atherosclerosis [19]. Overall, these seroepidemiological
studies have shown some limitations because diﬀerent
laboratories have measured diﬀerent antibody classes, used
diﬀerent criteria for determining seropositivity or measured
antibodies that were cross-reactive with other chlamydial
species. Although most of the studies have used the micro-
immunoﬂuorescence test (MIF) for measuring antibodies,
inter-laboratory variation in interpreting the results remains
ap r o b l e m[ 20, 21]. However, a number of experimental
data support the involvement of this pathogen in the patho-
genesis of atheroma [11–13]. First, C. pneumoniae gains
access the vasculature during local inﬂammation in lower
respiratory tract infection. Second, the infected alveolar
macrophages transmigrate through the mucosal barrier and
give the pathogen access to the lymphatic system, systemic
circulation, and atheromas. Third, C. pneumoniae can infect
a variety of cells commonly found in atheromas, including
coronary artery endothelial cells, macrophages, and aortic
smooth muscle cells. Fourth, C. pneumoniae may inﬂuence
atheroma biology by modulating macrophage-lipoprotein
interactions. In this setting, chlamydial lypopolysaccaride
(LPS), a potent endotoxin constituent of outer membrane
of Gram negative bacteria induces the release of cytokines
promoting leucocyte adherence, leucocyte migration, and
intimal inﬂammation. LPS has also been demonstrated to
have a crucial role in lipid metabolism [22] and it is involved
in mediating the process of “catching” LDL cholesterol by
macrophages infected with C. pneumoniae, which is trans-
formed into “foam cells,” the “key cells” of newly formed
atherosclerotic lesions [23]. Moreover, in vitro studies have
shownthatupregulatedmoleculesbyC.pneumoniae,includ-
ing -2 and 1-integrins, adhesion molecules (ICAM-1,
VCAM-1), platelet derived growth factor (PDGF), tissue
factor (TF), early growth response factor (EGR-1), appear to
contribute to these events. Some of these, along with matrix
metalloproteinases (MMPs) contribute to the destabilization
of atheromasic plaque, and the formation of thrombus [12]
and consecutively may lead to the arterial thromboembolic
complications. The link between C. pneumoniae and coro-
nary atherosclerosis is also substantiated by studies in which
antibodies against members of the HsPs family were detected
in individuals with persistent C. pneumoniae infections [9–
11, 24, 25]. Several ﬁndings indicate in fact that HsPs,
which are evolutionary very conservative and are present
in both microbial and host cells, seem to be important
in the development of autoimmunity. C. pneumoniae HsPs
are expressed in abundance in atherosclerotic lesions and
a persistent Chlamydia infection is accompanied by an
increased production of HsP60. In particular, this pro-
tein, may represent a particular antigenic stimulus capable
of eliciting strong humoral and cell-mediated immune
responses with immunopathological sequelae of chronic
chlamydial infections [9, 10, 12, 13, 26]. In this regard, C.
pneumoniae Hsp60 has been demonstrated in patients with
acutehemorrhagicevolutionofthecarotidplaquesuggesting
that C. pneumoniae might participate in the atherogenesis
andtoinduceatherosclerosiscomplicationsbyinﬂammatory
pathways (activation of cytokines, endothelial factors and
MMPs) [9]. At present, very little is known about genes
predisposing the host to the persistent C. pneumoniae
infectionanditssequelae.HLAhaplotypemarkershavebeen
recently investigated in patients with coronary artery disease
(CAD). In a recent study, a multiple logistic regression
analysis showed HLA-B∗35 allele as the strongest risk gene
for the combined serological markers of C. pneumoniae.
Male sex and smoking further strengthened the association
between HLA-B35 and markers of C. pneumoniae infection.
Interestingly, HLA-B∗35 was also found to be associated
with cardiovascular risk in Finnish patients [14].
2.2. C. pneumoniae and Stroke. The role of C. pneumoniae in
the pathogenesis of ischemic stroke is still debated. Infection
with C. pneumoniae may contribute to the risk of stroke
by enhancing CAD, as addressed in several issues. Several
published studies including the pilot case control “Northern
ManhattanStrokeStudy,”focusedonthecorrelationbetween
the C. pneumoniae infection, represented by the elevated
serum levels of speciﬁc anti-C. pneumoniae (IgA, IgG, and
IgM) antibodies at MIF test and stroke occurrence [26–
31], in diﬀerent race-ethnic groups and after adjusting for
conventional risk factors. The MIF method was used in
most of the previously published papers, as considered
as a reference standard in the C. pneumoniae serology.
The elevated titers of anti-C. pneumoniae IgA and IgG
were more prevalent in subjects with acute ischemic stroke
than in controls [26, 29–32]. With immunohistochemical4 Interdisciplinary Perspectives on Infectious Diseases
staining, other investigators demonstrated the presence of
C. pneumoniae in more than 70% of the endarterectomy
specimens from stroke patients with severe carotid stenosis
[33]. Other authors assessed anti-Chlamydia IgA and IgG
seropositivity using an ELISA test and found an increased
riskofstrokeinyoungpatientsseropositivetoC.pneumoniae
in the IgA antibody class rather than in IgG class [34].
This has suggested the possibility that IgA antibodies, which
last only 3 to 5 days in the circulation, are a diagnostic
marker of persistent, chronic infection (single IgA MIF titer
≥1:16), whereas IgG antibodies, which are produced for 3
to 5 years, are a marker of older, inactive infection [14]. The
association between IgA titers and risk of ischemic stroke
was also stratiﬁed according to ischemic stroke subtype. In
contrast with the less consistent evidence of an association of
IgA titers and cardioembolic and cryptogenic stroke, there
was a trend toward an association of IgA titers with large
vesselatheroscleroticandlacunarstroke,stronglysupporting
evidence that C. pneumoniae contributes to atherosclerosis
[30]. However, according to a previous consensus statement
[35] and other authors [36, 37], there is not yet agreement
that IgA titers are indicative of chronic, persistent infection.
First,thehalf-lifeofspeciﬁcC.pneumoniaeisonlyafewdays.
Second, measurement of IgA antibodies may be compli-
cated by cross-reacting C. pneumoniae IgG and rheumatoid
factor or with antibodies to other chlamydial species and
potentially other microorganisms. Third, MIF, the serologic
“golden standard” which may have been overestimated in
the past, is not standardized and there are interlaboratory
variations in the performance of this test [38]. Finally, the
hypothesis that C. pneumoniae infection, as indicated by
elevated IgA and IgG antibody titers, may be not associated
with an increased risk of ischemic stroke. This, however,
may diﬀer according to subtype of ischemic stroke, cut-oﬀ
value of antibody titers, and gender. Anti-C. pneumoniae
antibodies were also evaluated in HIV infected individuals
with CAD. One study showed that both the IgA and IgG lev-
els did not diﬀer signiﬁcantly and no subjects were positive
for IgM, suggesting that the damage to the carotid wall in
HIV-1 patients was not due to C. pneumoniae [39]. Other
studies by contrast, found that C. pneumoniae represents a
further risk factor for cardiovascular disease in HIV-positive
patients with both low CD4 cell count and high HIV load
[40] and that the coexistence of hypertriglyceridemia and
C. pneumoniae infection signiﬁcantly increases the risk of
atherosclerosis up to three times [41].
A number of studies addressed the question of whether
molecular tools and in particular PCR can be used to
detect chlamydial DNA in cerebrovascular atherosclerotic
lesions. The results provided from a consistent number of
atherosclerotic lesion and blood specimens from more than
1500 patients analysed by diﬀerent in-house PCRs, were
found extremely variable. Being PCR not standardized, this
technique has a tendency to produce false positive results.
In this setting, there is the need for standardization of PCR
methods and for assessing their sensitivity, speciﬁcity, and
predictive values. In general, there is not consensus on how
nested PCR (n-PCR) technology can be controlled [42].
PCRs have been shown to be predictive of CAD, when used
for detection of C. pneumoniae DNA in PBMC, suggesting
that the detection of bacterial DNA in PBMC may be a valid
surrogate marker to identify individual risk for endovascular
chlamydial infection [43]. Recently, C. pneumoniae DNA
and chlamydial LPS were measured during 12 months in 97
patients with acute CAD. C. pneumoniae DNA was detected
in PBMC from 8 (8.2%) patients at the initial hospitalization
during acute CAD and in 9 (10.6%) patients at 3 months. C.
pneumoniae DNA declined in stable state and in the recovery
period. These ﬁndings suggest a role of the bacterium in the
acute phase of CAD [44]. Attempts to eradicate C. pneumo-
niae in patients with cardiovascular diseases including the
“AzytromycinandCoronaryEventStudy”trial,haveallfailed
[45–47]. As shown in previous studies the persistent state is
completely refractory to antibiotic treatment [45] and ﬁrst-
choice antichlamydial drugs may even induce chlamydial
persistence under certain conditions [46]. In the absence of a
functional treatment strategy, the hypothesis of a chlamydial
contribution to atherogenetic processes can thus neither be
proved nor disproved by eradication studies, and a better
understanding of chlamydial pathobiology in order to target
speciﬁc chlamydial antigens is needed before implementing
clinical studies with new eﬀective antibiotic regimens.
In summary a causative role of C. pneumoniae infection
in cardiovascular disease has not yet been ﬁrmly established.
Despite the considerable laboratory and clinical research
that has been done on the role of C. pneumoniae in the
progression of atherosclerosis, several important questions
remain unanswered. Most importantly, it is not known
whether the C. pneumoniae bacterium is an innocent pas-
senger aboard atheromas or whether it is actively involved
in the initiation or progression of atherosclerotic disease.
To answer this question, well-planned studies are needed to
further characterize the molecular mechanisms that link C.
pneumoniae to vascular disease. In particular, HsP60 needs
to be explored further as a potential culprit and therapeutic
target. The early results from antichlamydial intervention
studies in humans are partially consistent with a causative
role of C. pneumoniae in the disease process.
3.C. pneumoniae,N e ur od eg e ne rati v e ,
andDemyelinatingDisorders
The ability of the C. pneumoniae to persist in monocytes and
macrophages in tissues for long periods, to circumvent the
mechanisms of bactericidal and oxidative stress, to activate
the endothelial cells with production of adhesion molecules
and cytokine overproduction, has suggested that it may
participate in the development or progression of certain
acute and chronic inﬂammatory diseases of the CNS. In
recent years, in fact, a growing body of evidence con-
cerning the involvement of C. pneumoniae in neurological
diseases has been gradually increasing. This was supported
in particular by the detection of genomic material of the
microrganism into the cerebrospinal ﬂuid (CSF) of patients
with multiple sclerosis (MS), Alzheimer’s disease (AD),
meningoencephalitis and neurobehavioral disorders [4, 6–
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3.1. Alzheimer’s Disease. Alzheimer’s disease (AD) is one of
the most severe dementing illnesses that increases with the
increasing age of the population. The disease is associated
with atrophy/death of neurons in particular regions of the
brain and occurs in two general forms: an early-onset
form that is primarily genetically determined, and a far
more common late-onset AD (LOAD), which is a non-
familial, progressive neurodegenerative disease that is now
themostcommonandsevereformofdementiaintheelderly.
The deﬁning neuropathology of both familial and sporadic
AD includes the neuritic senile plaque (NSPs), consisting
primarily of amyloid beta (Aβ) protein, and neuroﬁbrillary
tangles (NFTs), the major component being modiﬁed tau
protein, that aﬀect nerve synapses and nerve-nerve cell
communication. Genetic, biochemical, and immunological
analyseshaveinpartprovidedarelativelydetailedknowledge
of these entities [48, 55]. The disease usually manifests
initially as a gradual loss of short-term memory and later
progresses to major cognitive dysfunction. The latter can
take the form of various behavioural disorders, loss of
orientation, diﬃculties with language, and impairment of
daily living [56]. Estimates of crude incidence of AD range
from 7.03 to 23.8 per 1000 person years [57, 58]. The range
is likely attributable to diﬀerent study populations and case
investigating methods. The incidence of AD increases with
age for both genders, but there is deﬁnite indication if
there are gender diﬀerences. AD seems to be more common
among women with approximately a third higher incidence
and prevalence among females compared to males [59–61].
Using age-speciﬁc incidence rates one projection study in the
U.S. predicted that incident cases would increase from the
360,000 cases in 1997 to 1.14 million in 2047 [61]. Despite
the AD’s discovery by Alois Alzheimer in 1907, the cause
of this pathology and neurodegeneration is not unknown.
Infections of the CNS have been shown to stimulate inﬂam-
matory responses that may result in neurodegeneration [62].
S e v e r a lg r o u p sh a v ei n v e s t i g a t e da na s s o c i a t i o nb e t w e e n
various infectious agents and AD, but none of these has been
accepted as either etiological for disease development, or
worsening of neuropathology. Interesting perspectives came
from one study which identiﬁed herpes simplex virus type
1 (HSV-1) infection as a risk factor for development of
AD in subjects expressing APOE ε4a l l e l e[ 63, 64]. Virus
including measles virus, adenovirus, lentiviruses, and several
other others were initially considered but discarded after [65,
66]. Bacterial pathogens including C. trachomatis, Coxiella
burnettii, Mycoplama spp and spirochetes [67, 68] have also
been investigated and dismissed in relation to involvement
in AD neuropathogenesis. Prions have been also taken into
consideration but then excluded [69]. The ﬁrst paper that
reported an association between C. pneumoniae infection
and LOAD was from Balin et al. [48]. He found that 90%
of AD brains were positive for C. pneumoniae as assessed
by highly sensitive and speciﬁc PCR and the organism
was detected in various sections of brain (hippocampus,
cerebellum, temporal cortex, and prefrontal cortex) that
exhibited AD pathology of more or less variable intensity
[55]. Electron microscopic (EM) results revealed C. pneu-
moniae like particles containing EBs and RBs in the brain
tissue and immunohistochemistry analysis indicated strong
labelling in the sections of the brain most aﬀected by AD
amongthecases,whilenolabellinginthecontrols.Moreover,
a part the detection and visualization of C. pneumoniae
within the cells of CNS that were associated with plaques
and tangles, RNA transcripts of C. pneumoniae indicating
metabolically active organisms were demonstrated by RT-
PCR in frozen tissue samples and organisms were then
isolated from the tissue and propagated in cell cultures.
In that report, a strong association of APOE-ε4g e n o t y p e
and C. pneumoniae infection was found in 58% (11/19)
patients with AD suggesting, as shown in reactive arthritis,
that the APOE-ε4g e n em a yp r o m o t es o m ea s p e c t so fC.
pneumoniae pathobiologyinAD[48].TheBalinstudyreport
received a great deal of public and scientiﬁc attention and
attempts to replicate the ﬁnding were conducted in mother
reputable laboratories throughout the world. Two indepen-
dent investigators (Ossewaarde et al., 2000 and Mahony
et al., 2000, unpublished data) found C. pneumoniae in
brains of AD patients with PCR and immunohistochemistry,
validating Balin’s results. However, conﬂicting results were
found in subsequent studies by diﬀerent authors using
the same procedures but diﬀerent protocols in paraﬃn-
embedded brain tissues [49–53] attempting to revalidate
the previous ﬁndings (Table 1). These studies have yielded
contradictory results likely due to diﬀerences in diagnos-
t i cc r i t e r i aa n dd i a g n o s t i ct o o l s .D e m o g r a p h i cd i ﬀerences
between the patient groups, such as geographic location,
season of death and institutional history might also account
for these opposing results. AD patients included in the Balin
study, might have been recently exposed to C. pneumoniae,
perhaps in an institutional setting, and therefore would have
been at high risk of systemic spread from the respiratory
tract to sites within the CNS, where advanced AD pathology
already existed [70]. In a extension of these ﬁndings, Gerard,
two years later, demonstrated C. pneumoniae in 80% of AD
samples and 11.1% of the controls using primer targeting
two Chlamydia (1046, 0695) genes. The AD cases (mean
age 79.3 years) and controls (65.9 years) were age-and
sex-matched as closely as possible, but the controls were
younger and 22.7% were males [54]. The organism was
again viable within the AD brain as assessed by culture
of the organism from brain samples; moreover, RT-PCR
analyses identiﬁed primary rRNA gene transcripts from C.
pneumoniae indicating metabolic activity of the organism in
those tissues. Interestingly, immunohistochemical analyses
have also shown that astrocytes, microglia, and neurons all
served as host cells for C. pneumoniae in the AD brain,
and that infected cells were found in close proximity to
both NSPs and NFTs in the AD brain (Figure 1). Recently,
cultured astrocytes and microglia have also shown that C.
pneumoniae displays an active, not a persistent, growth
phenotype indicating probable concomitant destruction by
lysis of some portion of host cells at the termination of
that cycle [71]. In the years immediately after the study
of Balin, some experimental discoveries have provided
insights about the pathogenetic mechanisms of AD. First,
a relationship exists between possession of the APOE-ε4
allele and the pathobiology of C. pneumoniae [72] and that6 Interdisciplinary Perspectives on Infectious Diseases
(a) (b) (c)
(d) (e) (f)
Figure 1: Representative images of double immunolabelling studies to demonstrate the infection of astrocytes, microglia, and neurons
with Chlamydia pneumoniae in the AD brain. Chlamydia pneumoniae-infected cells were identiﬁed in all cases using the FITC-
labelled monoclonal antibody targeting the Chlamydia LPS (Pathﬁnder TM; a, c, e). Astrocytes (b) and microglia (d) were identiﬁed by
immunostaining using monoclonal antibodies targeting GFAP and iNOS, respectively. Neurons were identiﬁed by immunostaining with a
monoclonal antibody targeting neuron-speciﬁc microtubule-associated protein (f). Images in all panels were obtained using a objective. In
all panels, arrows indicate cells labelling with the Pathﬁnder TM and surface marker-speciﬁc monoclonal antibodies. (Reproduced from [54]
with courtesy of Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI, USA, and with
permission of FEMS Med Lett).
Table 1: Studies demonstrating evidence or absence of C. pneumoniae in brain autoptic specimens from patients with Alzheimer disease.
Author, year
No. of autoptic AD
brain specimens
examined
C. pneumoniae DNA
detection and
conﬁrmation
methods
Results of ∧PCR in
AD brain Positive %
Results of PCR in
control brain Positive
%
Study of APOEe 4
gene expression
Balin et al. 1998 [48] 19
§PCR, / =RT-PCR,
∧∧IHM, ∗EM,
Culture
1790 15,2 Yes
Nochlin et al. 1999 [49] 13 †PCR, IHM 0 - 0 - Not done
Gieﬀers et al. 2000 [50] 20 ◦PCR, IHM 0 - 0 - Not done
Ring and Lyons 2000 [51] 15 ◦◦PCR, Culture 0 - 0 - Not done
Taylor et al. 2002 [52] 10 •PCR, IHM 0 - 0 - Not done
Wozniak et al. 2003 [53] 4 ◦◦◦PCR 0 - 0 - Not done
G´ erard et al. 2006 [54] 27
‡PCR, RT-PCR, IHM,
EM, Culture 2580 311 Yes
∧PCR, polymerase chain reaction; / =RT-PCR, Reverse transcriptase PCR; ∧∧IHM, immunoistochemistry; ∗EM, electron microscopy; §primers targeting the
16S ribosomal RNA (rRNA) gene (Gaydos et al., J Clin Microbiol 1992; 30: 796–800) and the chlamydial major outer membrane protein (MOMP) gene
(ompA) (Perez-Melgosa et al., Infect Imm 1991; 59: 2195–9); †PCR with seminested primer amplifying C. pneumoniae-speciﬁc DNA sequences of 437bp
(Kuo et al, J Infect Dis 1993; 167: 841-9); ◦nested PCR (Maass et al., Atherosclerosis 1998; 140: S25–30); ◦◦Primers targeting the MOMP gene (Perez-Melgosa
et al., 1991; Infect Imm 1991; 59: 2195–9) •PCR using the 76kDa protein gene [47], the rpoB gene encoding the RNA polymerase beta subunit (Ouchi et
al., J Med Microbiol 1998; 47: 907–13), and the pan-Chlamydia primers targeting the 16S ribosomal RNA gene in Chlamydia and Chlamydia-like organisms
(Ossewaarde et al., Microbiology 1999; 145: 411–17); ◦◦◦PCR with primer targeting the 16SrRNA gene (J Clin Microbiol 1992; 30: 796–800); ‡PCR-multiple
assays targeting the Cpn1046 gene (aromatic amino acid hydroxylase) and Cpn0695 (MOMP)[54].
the C. pneumoniae load in the AD brain varies with APOE
genotype [73]. Second, infection of human microvascular
endothelial cells co-cultured with C. pneumoniae elicits
increased expression of proteins relevant to access for the
organism to CNS including N-cadherin and b-catenin [74].
Third, the expression of occludin, a protein associated with
tight junctions, is attenuated in the C. pneumoniae-infected
cells. Fourth, infection with C. pneumoniae through the
olfactory pathways of nontransgenic young female BALB/c
mice which usually do not develop AD, has shown toInterdisciplinary Perspectives on Infectious Diseases 7
promote the production of extracellular amyloidlike plaques
(Aβ1-42) in the mouse’s brain thus providing a unique
model for the study of sporadic AD and suggesting that this
modelcouldbeaprimarytriggerforADpathologyfollowing
a noninvasive route inoculation [75]. Since C. pneumoniae
is harboured in the respiratory tract and has a predilection
for infecting epithelial cells, the olfactory neuroepithelia in
the nasal passages are a likely target for infection. Following
entry into these epithelia, potential damage and/or cell death
may occur in the main olfactory bulb and olfactory cortex,
thereby setting the stage for further retrograde neuronal
damage [55].
Because chlamydial chronic infections are characterized
by the inaccessibility of the “chlamydial persistent state” to
conventional antichlamydial agents, there are few clinical
trials that have determined the eﬀectiveness of antibiotic
therapy against C. pneumoniae in AD. A ﬁrst randomized,
placebo controlled, multicentre clinical trial performed to
determine whether a 3-month course of doxycycline and
rifampin could reduce the decline of cognitive function in
patients with AD showed signiﬁcantly less cognitive decline
at 6 months and less dysfunctional behaviour at 3 months,
in the antibiotic group than in controls [76]. Although
these observations do not demonstrate a causal relationship
between CNS infection with C. pneumoniae in terms of
eradication of chronic C. pneumoniae infection and the
AD neuropathogenesis, they do open the way to further
investigations. In this regard, animal modelling will be
required to deﬁne in detail how chlamydial infection might
result in AD-related pathological change in the CNS and
to provide a better understanding of infection parameters.
In vitro and mouse model studies have demonstrated that
metalproteinattenuatingcompounds(MPACs)promotethe
solubilisation and clearance of extracellular senile plaques
comprised of beta-amyloid. The role of the antiprotozoal
metal chelator clioquinol in AD, which has been reported
to reduce beta-amyloid plaques, presumably by chelation
associated with copper and zinc, is currently in clinical trials
as potential for treatment of AD [77, 78]. The scientiﬁc
knowledge surrounding Alzheimer’s disease and infection by
C. pneumoniae is still growing. Standardization of diagnostic
techniques would certainly allow for better comparability
of studies. However, other systemic infections as potential
contributorstothepathogenesisofADshouldbeconsidered.
3.2. C. pneumoniae and AIDS Dementia. Many authors have
explored the possibility that C. pneumoniae was involved in
other neurodegenerative disorders other than Alzheimer’s
disease. The existing data are however few and not signif-
icant. Among those characterized by dementia, one study
performed by our group explored the possible link between
AIDS-dementia complex (ADC) and C. pneumoniae [79].
ADC is an HIV-derived neuropathological disorder charac-
terised by infection of macrophages and microglia cells and
release of proinﬂammatory cytokines into the parenchyma
[80]. In this report, C. pneumoniae was identiﬁed in the CNS
by PCR for C. pneumoniae MOMP and 16S rRNA gene in 4
(17.4%) out of 23 HIV-infected patients diagnosed as ADC
Stage 3 according to scheme for AIDS dementia complex and
conﬁrmed by autopsy. Sequence analysis revealed signiﬁcant
homologies with C. pneumoniae compared to C. trachomatis
and C. psittaci. Moreover, high mean levels of CSF speciﬁc
anti-C. pneumoniae antibodies and C. pneumoniae antibody
speciﬁc index values signiﬁcantly elevated were also found
by ELISA in these patients. These ﬁndings suggest that
although the low rate of isolation is not representative of
the frequency with which C. pneumoniae is involved in the
causation of CNS injury, in the late-stage HIV infection,
an increase in “traﬃcking” of monocytes containing C.
pneumoniae to the brain may carry this organism in the sites
which are the major reservoirs of productive HIV replication
and contribute to neuronal damage in HIV-infected patients
[79]. Moreover, the possibility that may exist a patient’s
subgroupinwhomthisorganismisnot,asforatherosclerosis
and other Chlamydial diseases, an “innocent bystander,” but
may survive and replicate in CNS macrophages cannot be
excluded [8].
3.3. C. pneumoniae and Multiple Sclerosis. MS disease is a
presumed autoimmune chronic inﬂammatory disease of the
CNS of unknown aetiology triggered by an environmental
factor in susceptible individuals. It generally aﬀects 1 to 1.8
per 1,000 individuals and kills more than 3000 people each
year,withafurtherestimatedannualmorbiditycostofover$
2.5billion.IntheUnitedStates,theprevalenceofthediseases
is 250,000 to 350,000 cases annually [97]. The pathological
hallmark of multiple sclerosis (MS) is the demyelinating
plaque that represents an area of demyelination and gliosis
around blood vessels [98]. Acute lesions show perivascular
lymphocytes and plasma cells along with the inﬁltration
of macrophages and phagocytosis of myelin membranes.
The continuous breakdown and regeneration of myelin has
been demonstrated within the progressive MS plaque [99].
Toll-like receptors (TLR) are intimately involved in several
neurodegenerative and demyelinating disorders including
MS as demonstrated with the ﬁnding of a marked increase in
TLR expression in MS lesions. PCR studies have shown that
microglial cells from MS patients express TLRs 1–8 [100].
Moreover, while healthy white matter from MS patients does
not contain TLRs, active lesions are associated with high
expression of TLR3 and TLR4 on microglia and astrocytes.
In contrast, late active lesions also contain astrocytes bearing
surfaceTLR3andTLR4[100].Thissuggeststhatearlylesions
are characterized by microglia inﬁltration, while astrocytes
are also active in later MS lesions. However, the precise role
ofTLR3andTLR4activationintheselesionsisyetunknown.
TLRshave beenshowntorecognize highly conservedregions
in various microorganisms (Pathogen-Associated Molecular
Patterns) including C. pneumoniae and thus stimulate a
potent inﬂammatory response contributing to the clearance
of the pathogen [101]. Unpublished our ﬁndings have
detected the major expression of mRNA TLR-2 and TLR-
4 in peripheral blood but not in CSF from SM patients
with RR forms, indicating that their combined activity
might be crucial to modulate and activate the cellular-
mediated immune response during chronic infections by C.
pneumoniae [102]. Based on epidemiological observations, it8 Interdisciplinary Perspectives on Infectious Diseases
has been proposed that exposure to an environmental factor,
such as an infectious agent, in combination with genetic
predisposition could be implicated in MS pathogenesis
[103]. The risk of MS is enhanced by the presence of speciﬁc
genes on chromosome 6 in the area of MHC, Human
Leukocyte Antigens (HLA) in humans. In particular, HLA-
DR and HLA-DQ genes, which are involved in antigen
presentation, are strongly associated to the development of
the disease. However, although the risk of the disease is
higher in monozygotic than in dizygotic twins (about 30%
and 5%, resp.), the low concordance rate obtained in iden-
tical twins suggests that non-genetic factors can contribute
to MS aetiology. In this setting, the aetiopathogenesis of
MS disease is complex and still debated. So far, about 20
microorganisms including viruses have been associated with
this disease [104]. The screening techniques in these studies
varied from serology to PCR and quality and numbers of
controls examined varied widely. The latest pathogen to be
associated with MS is C. pneumoniae [105–110]. Sriram et
al. reported the ﬁrst evidence suggesting the potential role
for C. pneumoniae as a candidate in MS pathogenesis [106].
One year later, a larger study from the same group strongly
conﬁrmed that CSF demonstration of C. pneumoniae was
more frequent in MS patients than in control patients with
other neurological disorders (OND) [107]. In particular, C.
pneumoniae culture isolation was obtained in 24/37 (65%)
MS and in 3/27 (11%) OND patients, CSF single polymerase
chain reaction (PCR) for major outer-membrane protein
(MOMP) was positive in 36/37 (97%) MS and in 5/27
(18%) OND patients, whereas CSF anti-C. pneumoniae IgG
were detected by enzyme linked immunoadsorbent assay
(ELISA) in 32/37 (86%) MS and in 0/27 (0%) OND patients.
After this innovative publication, a number of studies have
suggested that C. pneumoniae infection may be associated
with MS, while other studies have found no association [108,
109]. During recent years, there have been many evidences
of a possible role of C. pneumoniae involvement in MS
disease supported in part by seroepidemiological, cultural,
molecular,immunologicalandtherapeuticstudies.However,
it is also true that there are not many studies that argue for
a role of organism in MS. First, while some reports have
documented that C. pneumoniae seropositivity was related
to the risk of MS progressive forms (SP and PP), but only
moderately linked to the risk of developing MS [110], others
have not found association between serum titers of anti-C.
pneumoniae antibodies and the risk for MS or, by contrast,
a higher risk to develop MS in a subgroup of older patients
after than before disease onset [111]. Second, the organism
was found in course of MS relapses in the throat together
with a rising serology [112]. Third, relapses of MS have
long been noted to follow respiratory infections, including
sore throat, or pneumoniae with a clinical pattern typical of
respiratory infection caused by C. pneumoniae. The isolation
of the pathogen, as assessed by culture assay in CSF and
brain tissue failed repeatedly in MS patients [113–115]o r
was positive only in a small proportion of MS patients
[81, 116]. Dong-Si et al. have noted gene transcription
of messenger RNA by C. pneumoniae in CSF from MS
patients suggesting active infection by this pathogen [91].
Recently, active transcription of DNA from the organism
has been found in a persistent and metabolically active state
in cultured CSF and PBMCs from MS patients, but not
in controls [95]. Other investigators were able to culture
and detect C. pneumoniae in buﬀyc o a ts a m p l e sf r o ma
healthy blood donor population [117] demonstrating a
Chlamydia carriage rate of 24.6%, within the WBC of the
peripheral circulation. Because of the diﬃculties of isolating
C. pneumoniae cultures, nucleic acid ampliﬁcation methods
such as PCR-based assays have become the method of
choice for detection of this microorganism. However, PCR
procedures often diﬀer in several aspects which can aﬀect
sensitivity, reproducibility, and speciﬁcity when applied to
direct testing of clinical specimens [86, 118, 119]. In this
context, collaborative studies involving diﬀerent laboratories
in which the presence of C. pneumoniae was evaluated in
blinded CSF samples, further underlined the lack of an
accepted standardized PCR protocol [120, 121]. A number
of PCR studies did not provide evidence of detection of
C. pneumoniae DNA in CSF of MS patients. Most of these
studies were performed using single or nested (n) PCR
targetingeitherMOMPor16Sribosomal(rRNA)chlamydial
genes [11, 34, 114, 116, 122–124]. By contrast, a substantial
body of work from around the world has provided clear
evidence of the involvement of C. pneumoniae in MS. In
this setting, a consistent number of studies did found PCR
positive results with DNA or mRNA positive rates varying
from 2.9% to 69% [81–91]; [94–96]; [117–126]a sl i s t e di n
Table 2. Somereportsalsodemonstratedthemorefrequency
of C. pneumoniae DNA in CSF of MS patients with Gd
enhancing lesions on MRI scans [87, 89]. Moreover, CSF
detection of heat-shock protein-60 messenger RNA (Hsp-60
mRNA) and 16S rRNA by Reverse-Transcriptase PCR (RT-
P C R )w a sm o r ef r e q u e n ti nM Sp a t i e n t st h a ni nc o n t r o l s
signifying the presence of a high rate of gene transcription
and, therefore, more active metabolism of C. pneumoniae in
MS [91]. In 2004, our group developed a novel ampliﬁcation
program for MOMP gene by employing a “touchdown”
technique and analyzing CSF samples from patients with
MS, other inﬂammatory neurological disorders (OIND)
and noninﬂammatory neurological disorders (NIND) and
employed three gene targets (MOMP, 16S rRNA and HsP-
70) in parallel to achieve a major sensitivity and speciﬁcity
[92]. A PCR positivity for MOMP and 16S rRNA in CSF was
presentinasmallproportionofMS(37%),OIND(28%)and
NIND (37%) patients, without any diﬀerences between MS
and controls. Furthermore, a PCR positivity for MOMP and
16S rRNA in CSF was more frequent in relapsing-remitting
(RR) MS than in MS progressive forms (SP and in PP MS) as
well as in clinically and magnetic resonance imaging (MRI)
active than in clinically and MRI stable MS, whereas a CSF
PCR positivity for HsP-70 was observed in only three active
RR MS patients. Thus, it cannot be excluded that, in a
particularsubgroupofRRactiveMSpatients,C.pneumoniae
may enter into brain early in the course of the disease via
transendothelial migration across the blood/brain barrier
of activated infected blood-borne monocytes, resulting in
ongoing inﬂammatory immune activation that takes place
within the CNS. Alternatively, the presence of elevated ratesInterdisciplinary Perspectives on Infectious Diseases 9
Table 2: Molecular protocols employed for detection of C. pneumoniae in clinical specimens from MS patients.
MS patients
(positive/total)
Controls (positive/total) PCR assay References
7/30 (23%) 0/56 (0%) n-PCR† Layh-Schmitt et al.
2000 [81]
9/17 (52%) 13/15 (86%) PCR† Li et al. 2000 [82]
2/8 (25%) not reported† Treib et al. 2000 [83]
12/58 (21%) 20/47 (43%) n-PCR† Gieﬀers et al. 2001
[84]
3/32 (9%) 0/30 (0%) PCR† Sotgiu et al. 2001 [85]
11/16 (69%) PCR† Ikejima et al. 2001
[86]
9/28 (32%) 2/15 (13%) PCR† Hao et al. 2002 [87]
2/70 (2.9%) 0/30 (0%) n-PCR† Chatzipanagiotou et
al. 2003 [88]
23/107 (21%) 2/77 (3%) Touchdown n-PCR† Grimaldi et al. 2003
[89]
2/25 (8%) 3/28 (11%) n-PCR and semi-n-PCR† Rostasy et al. 2003
[90]
42/84 (50%) 25/89 (28%) Touchdown n-PCR, RT-PCR† Dong-Si et al. 2004
[91]
26/71 (36.6%) 24/72 (33.3%) Touchdown n-PCR† Contini et al. 2004
[92]
12/20 (60%) 1/12 (8%) Touchdown n-PCR† Sriram et al. 2005 [93]
2/112 (2%) 0/110 (0%) Real-time PCR‡ Sessa et al. 2007 [94]
7–9/14 (50–64.3%)† 0-1/19 (0–5.2%)† Touchdown n-PCR, Contini et al. 2008
[95] 5–7/14 (35.7–50%)‡ 0–2/19 (0–10.5 %)‡ RT-PCR†‡,
64/80 (80%) 5/57 (9%) PCR-EIA, Touchdown n-PCR, Real Time-PCR† Tang et al. 2009 [96]
n-PCR: nested PCR; RT-PCR: reverse transcriptase PCR; PCR-EIA: PCR enzyme immunoassay; †, CFS: cerebrospinal ﬂuid; ‡, PBMC: peripheral blood
mononuclear cells.
of C. pneumoniae DNA in CSF in this subset of MS patients
could merely reﬂect the selective inﬁltration of monocytes
which traﬃc into the brain after activation, thus suggesting
ar o l ef o rC. pneumoniae only as a silent passenger. In
attempting to recover C. pneumoniae from cultured CSF and
PBMC compartments with a PCR targeting multiple genes,
a positivity for C. pneumoniae DNA and mRNA was recently
detected in 64% of cocultured CSF and PBMCs of RR MS
patients with evidence of disease activity, whereas only 3
controls were positive for Chlamydial DNA, suggesting that
C. pneumoniae may occur in a persistent and metabolically
active state at both peripheral and intrathecal levels in MS,
but not in controls [95]. In this study the parallel molecular
analysis of multiple Chlamydial target genes after co-culture
of fresh CSF and PBMC specimens, has shown to enhance
the sensitivity and speciﬁcity of molecular tools. Of note, as
C. pneumoniae DNA was found in PBMCs which are able to
cross the blood-brain barrier, these cells could be the source
of intrathecally compartmentalized C. pneumoniae that, in
turn, may induce a chronic persistent brain infection acting
asacofactorinthedevelopmentofthedisease.Morerecently,
in a comparative study aimed to evaluate novel procedures
for the detection of C. pneumoniae DNA in CSF, the
qualitativecolorimetricmicrotiterplate-basedPCR-enzyme-
immunoassay (PCR-EIA) has shown to be more sensitive
than a real-time quantitative PCR assay (TaqMan) and
possessed a sensitivity that was equal to the nested-PCR [96].
In order to support the theory of an association between C.
pneumoniae and MS, a number of studies did evaluate the
presence of intrathecal IgG in the form of oligoclonal bands
(OCB) in the CSF of MS patients. Their presence, as for
other bacterial, viral, fungal, and parasitic diseases, would
be of great evidence for an infectious cause of MS [127]a n d
mayreﬂectanantigen-driven immune responsetoinfectious
agents [128]. However, OCB are also detected other than
in MS in 10% of patients with other inﬂammatory diseases
of the CNS. In this regard, studies aimed to determine
the CSF levels of anti-C. pneumoniae IgG in MS patients
did result extremely variable (varying from 0% to 20%)
producinganyorscarcediﬀerencesbetweenMSandcontrols
[81, 85, 87, 90, 122, 123, 126, 129, 130]. Recently, we
found that an intrathecal synthesis of anti-C. pneumoniae
IgG as evaluated by antibody speciﬁc index (ASI) was more
frequent in MS (16.9%) and in OIND (21.6%) than in
NIND (1.9%) patients and in patients with MS progressive
forms (SP and PP MS) than in RR MS patients [131].
Moreover, among the patients with intrathecally produced
anti-C. pneumoniae IgG, CSF C. pneumoniae-speciﬁc high-
aﬃnity antibodies, were demonstrated to be more frequent
in a subset of patients with MS progressive forms (SP or10 Interdisciplinary Perspectives on Infectious Diseases
PP MS), than in OIND patients, and absent in RR MS and
NIND patients. To further examine a possible relationship
between C. pneumoniae infection and MS, Sriram published
a study that examined autoptic samples of brain tissue
and CSF using immunohistochemical staining with anti-C.
pneumoniae monoclonal antibodies other than molecular
andultrastructuralmethods[93].Thesetechniquesprovided
evidence of the presence of C. pneumoniae more commonly
in MS patients (90%, 62%, and 55%, resp.) than in
control patients. Using electron microscopy the authors ﬁrst
demonstrated the presence of immunogold-labeled objects
of the morphology and size and of chlamydial EBs in the
ependymal surfaces and periventricular regions in the CSF
of four out of ten (40%) patients with MS but not in the
CSF of control patients. Collectively taken, although MS
patients were found to be more likely to have detectable
levels of C. pneumoniae DNA in their CSF and intrathecally
synthesized immunoglobulins, compared with patients with
had neurological diseases, the overall ﬁndings examined
in a review through 26 studies that considered 1332 MS
patients and 1464 controls using random-eﬀects methods
and random-eﬀects meta-regressions, adjusted for the con-
founding eﬀect of gender diﬀerences, were insuﬃcient to
establish an etiologic relation between C. pneumoniae and
MS [132].
The treatment directed against the inﬂammatory process
is only partially eﬃcacious on the MS disease course. In
relapsing-remitting MS, such therapy slows the progression
ofdisability,butinprimary-progressiveMSthesametherapy
has demonstrated to have little or no eﬀect on the pro-
gression of disability. On the other hand, reports regarding
the antimicrobial treatment of MS have provided conﬂicting
results. In one trial the antibiotic minocycline resulted in
a reduction in the number of gadolinium-enhancing MRI-
detected lesions [133]. Another study showed that anti-
chlamydial treatment reduced brain atrophy, but did not
show any beneﬁcial inﬂuence on the number of MRI Gd
enhancing lesions [134]. The Vanderblit University group
is currently treating patients with MS with a combination
of bacterial protein synthesis inhibitors (doxycycline and
azithromycin or roxithromycin or rifampicin) and then
adding metronidazole to this. These studies will need to be
validated by comprehensive multicenter trials of combined
antibiotictreatmentaimedatallphasesoftheorganism’slife-
cycle [135].
From the data presented, there is strong evidence that
C. pneumoniae has not a causal role in MS disease. Thus,
the actual involvement of C. pneumoniae in MS still remains
a matter of debate and requires further understanding
through standardized cultural, molecular and ultrastructural
protocols for C. pneumoniae in biological samples coming
from MS patients and controls. While some studies suggest
ar o l eo fC. pneumoniae only as a CNS innocent bystander
epiphenomenon due to ongoing MS inﬂammation which
favours a selective inﬁltration of infected-mononuclear cells
within the CNS, others indicate a role of C. pneumoniae as
a cofactor in development and progression of the disease by
enhancing a pre-existing autoimmune response in a subset
of MS patients, as supported by recent immunological and
molecular ﬁndings [95, 109, 136]. Recent our ﬁndings have
demonstratedapossibleassociationbetweenParachlamydiae
Like Organisms and MS suggesting that these can act
a l o n eo rt o g e t h e rw i t hC. pneumoniae as a cofactor in the
development and progression of MS [137]. Although these
data needs further assessment, their possible involvement in
MS could be of great importance in public health.
Finally, we cannot exclude that other pathogens may
be potentially involved in the development of MS disease.
Virus have often been considered as potential candidates
because they are known to cause demyelinating disease in
experimental animals and man, and often cause disease with
long periods of latency that presents clinically with relapsing,
remitting symptoms [138]. To date, however, studies have
failed to identify any single virus as playing a major role in
MS. Among the virus suggested as MS cofactors, there are
ubiquitous members of the family Herpesviridae, Human
herpesvirus 6 (HHV-6), Epstein-Barr virus (EBV) [139–
146]. As Chlamydia, these viruses can undergo an alternative
infection cycle, entering a quiescent state (latency), with low
grade viral infection that does not cause cell lysis, from
which they subsequently can be reactivated. However, the
cell type in which this occurs is usually not the same cell
type in which the productive, cytocidal infection occurs.
The human MS-associated retrovirus (MSRV) belonging to
endogenous retrovirus family, has been also described as
potential pathogen in MS [147].
4.C. pneumoniae and Other
Neurological Complications
A number of reports have focused on the involvement of
C. pneumoniae in other CNS disorders and in particular in
encephalitis or meningoencephalitis. We searched PubMed
for articles on encephalitis and Chlamydia pneumoniae
or Chlamydophila pneumoniae using keywords: encephali-
tis, meningoencephalitis, Chlamydia pneumoniae, Chlamy-
dophila pneumoniae, and numerous additional keywords
including “neurological complications” relevant to these
topics. Due to the common usage of the previous genus
name, “Chlamydia,” it was included in the search. The
reported cases (Table 3) were not so frequent [148–159].
Most patients were young patients who presented with
diﬀerent neurological symptoms and/or neuro-radiological
changes at CT or MRI scan and in most cases, there were also
well deﬁned accompanying respiratory symptoms, although
these have in some cases preceded the onset of the neuro-
logical records. Three patients had cerebellar ataxia, acute
demyelinating encephalitis (ADEM), and Guillain Barr` e
syndrome. The detection of Chlamydia has been almost
always done by serological methods based on detection of
speciﬁc anti-C. pneumoniae antibodies of diﬀerent classes by
MIF (fourfold rise in the IgG titre) and ELISA techniques.
One study detected the presence of IgA-type antibodies,
suggesting a reinfection [158] .O n en o t er e p o r t e dt h eu s eo f
PCR in a tracheal swab and increasing titres of Chlamydia
IgM antibody [155]. These cases, and a review of the
literature,suggestthatC.pneumoniaeinfectioninadditiontoInterdisciplinary Perspectives on Infectious Diseases 11
Table 3: Acute and chronic neurological complications preceding or following C. pneumoniae associated respiratory manifestations.
Author, year Patient
n.
Sex/age
range (yr)
median
Clinical ﬁndings C. pneumoniae
detection Neuroimaging Treatment Outcome
Fryden et al.
1989 [148] 1F / 1 6
Encephalitis,
respiratory tract
infection
Serum (4-fold rise) in
IgG and IgM§ CSF
negative for IgG and
IgM
Brain CT scan Clorampheni-col,
Steroids
Recovery 1 year
later
Haidl et al. 1992
[149] 1M / 1 3
Guillan-Barr` e
syndrome, parestesia,
hyporeﬂexia, cough
Serum (4-fold rise) in
IgG and IgM§ ND Steroids
Recovery 5
weeks later
Michel et al.
1992 [150] 1M / 9
Meningoradicultis,
cough, rhinitis,
hyporeﬂexia, back
stiﬀness
Serum 4-fold fall in
IgM, CSF positive for
total IgG
ND ND
Recovery 6
months later
Sundel¨ of et al.
1993 [151] 1M / 1 8
Meningoencepha-
litis, headache,
diplopia paresthesia,
fever, cough
Serum IgG (4-fold),
IgM§ CSF negative
for IgG and IgM
Brain CT scan
Erythromycin,
Cefotaxime,
Acyclovir
Recovery <1
week later
Socan et al. 1994
[152] 1M / 1 8
Diplopia, parestesia,
meningeal syndrome,
cough and
pneumoniae
Serum IgM and IgG§
CSF negative for IgG
and IgM
Brain CT scan
Acyclovir,
Cefotaxime,
Erythromycin
Recovery <1
week later
Koskiniemi et al.
1997 [153] 3F 2/5.6
Pareses, sensory
symptoms,
convulsions,
depression of
conscious-sness
Serum IgM and IgG§ Brain CT, EEG## Unspeciﬁed ND
Korman et al.
1997 [154] 1F / 6 9 Cerebellar ataxia,
respiratory failure
Serum (4-fold rise) in
IgG, elevated IgA§
CSF negative for IgG
and IgM
Brain CT Erythromycin,
Imipenem
Recovery <1
month later
Heick and
Skriver 2000
[155]
1F / 1 8
Coryzal illness,
headache, dizziness,
left-sided hemiparesis
(†ADEM), ataxia,
fever, dry cough
CKT# in serum serum
IgM PCR in tracheal
swab
Brain CT scan,
cranial MR
Penicillin,
Acyclovir,
Gentamycine,
Cefotaxime,
Doxycycline,
Methylpredn-
isolone
Recovery 2
months
Guglielminotti
et al. 2000 [156] 1M / 9 5 Meningeal syndrome,
sleepiness, dry cough
Serum (4-fold rise) in
IgG and IgA§ CSF IgG Brain CT, EEG
Acyclovir,
Amoxicillin,
Erythromycin,
Oﬂoxacin
died aspiration
pneumoniae
Anton et al.
2000 [157] 1F / 1 6
Hyporeﬂexia, bilateral
nistagmus, sleepiness,
motor weakness,
rhinitis
Serum (4-fold rise) in
IgG, IgM§ CSF
negative for IgG and
IgM
Brain CT scan,
Brain MR,
Electrophy-
siological
studies
Ceftriaxone,
Methylpredn-
isolone
Recovery 2
months later
Airas et al. 2001
[158] 1F / 3 3
Sleepiness, memory
loss, cough,
pharyngitis
Serum IgA and IgG‡ Brain MR
Acyclovir,
Levoﬂoxacine,
Azhitromycine
Partial
improvement
Boschin-
Crinquette et al.
2005 [159]
1M / 2 1
Aphasia, meningeal
syndrome, respiratory
symptoms
Serum IgM◦ CSF
negative for IgM, IgG
and PCR
Brain CT scan,
Brain MR
Acyclovir,
Oﬂoxacin
Amoxicillin,
Cefotaxime
Recovery <2
weeks later
§MIF: microimmunoﬂuorescence; ‡EIA: enzyme immunoassay; ◦ELISA: enzyme-linked immunoadsorbent assay; #CTK: Chlamydia Complement-binding
Test; ##EEG: electroencephalogram; †ADEM: acute disseminated encephalomyelitis.12 Interdisciplinary Perspectives on Infectious Diseases
other Chlamydiae, may present with signiﬁcant neurological
manifestations.Ofinterest,mostofthesepatientsdidexperi-
ence a favourable outcome after administration of antibiotic
therapy with or without corticosteroid treatment, suggesting
a strong etiologic link between the microorganism and
encephalitis. Chlamydial infections along with Mycoplasma
and legionella infections should be included in the diﬀer-
ential diagnosis of respiratory infections with a neurologic
presentation.
5.C. pneumoniae and
NeurobehavioralDisorders
Although the limited data of literature, there is evidence
that Chlamydia may be implicated in the pathogenesis of
some mental or neurobehavioral disorders including autism
and schizophrenia. Autism spectrum disorders (ASDs) are
a group of neurobehavioral diseases of unknown aetiology,
which include autism, attention deﬁcit disorder, Asperger’s
syndrome, and so forth, which causes are unknown but
appear to include genetic defects, heavy metal, and chemical
and biological exposures [160]. Factors, such as geography,
family socioeconomic status, vaccination records, and family
educationallevelsmaybealsoinvolved.Theyoccurprimarily
in the young and are probably diﬀerent in each patient.
Such patients do not all share the same signs and symptoms
but tend to share certain social, communication, motor, and
sensory problems that aﬀect their behaviour in predictable
ways. In general, the criteria for diagnosis of ASD are the
presence of a triad of impairments in social interaction,
communication, and imagination [160]. These signs and
symptoms are thought to be due to abnormalities in brain
function or structure and are thought to have a genetic
basis [161, 162] .T h e r ei sg r o w i n ga w a r e n e s st h a tA S D
can have an infectious nature that may be a cofactor for
the illness or can aggravate patient morbidity [163–165].
The appearance of infections and in particular Mycoplasma
infections in children diagnosed with ASD has been also
linked to the multiple vaccines received during childhood
[136, 166]. In this setting, C. pneumoniae [167, 168]a l o n g
with a number of systemic chronic infections, such as those
by Mycoplasma species [169–172] and HHV-6 [171–173],
have been identiﬁed in Gulf War veterans and in family
membersincludingtheirchildren,usinghighlysensitivePCR
and conﬁrming the results by Southern-blot and dot-blot
hybridization. Interestingly, a number of these symptomatic
children were diagnosed with autism or attention deﬁcit
disorder that fall under ASD [174] .B a s e do np r e vi o u so b s e r -
vations of persisting IgA titers in some patients with mental
disorders, it has been hypothesized that Chlamydiaceae are
main pathogenic factors in schizophrenia. Fellerhoﬀ, using
n-PCR, found a signiﬁcant prevalence of C. psittaci, C.
pneumoniae, and C. trachomatis (9/18, 50%), as compared
to controls (8/115, 6.97%). Treatment with in vitro-activated
immune cells together with antibiotic modalities showed
sustained mental improvements in patients that did not
depend on treatment with antipsychotic drugs [175].
6. Conclusions
C. pneumoniae is like a “New Bug that’s full of Surprises”
[136]. This perfectly matches to the wide range of chronic
diseases which can be sustained by this pathogen. Thanks to
deep knowledge of the biology of Chlamydia and the use of
increasinglysophisticatedtechniquesthanthosetraditionally
used, the presence of C. pneumoniae genomic material was
demonstrated in a large number of persons suﬀering from
diﬀerent acute and chronic diseases. Over the past 10 years,
a growing number of reports have found a possible link
between C. pneumoniae infection and atherosclerosis and
CNS diseases including MS, AD other than a variety of
neurobehavioral disorders. The main obstacles that have so
far presented to support a deﬁnitive role of C. pneumoniae in
chronic diseases are represented by the fact that no methods
exist to safely and conﬁdently diagnose chronic infection,
and because chlamydial chronic infections are characterized
by the inaccessibility of the “chlamydial persistent state” to
conventional antichlamydial agents. A causative role of C.
pneumoniae infection in cardiovascular disease has not yet
been ﬁrmly established. Despite the molecular and genetic
eﬀorts that have been done on the role of C. pneumoniae in
the progression of atherosclerosis, several important ques-
tions including whether the C. pneumoniae is an innocent
passenger or whether it is actively involved in the initiation
or progression of atherosclerotic disease urgently need an
answer. In particular, C. pneumoniae HsP60 needs to be
explored further as a potential culprit and therapeutic target
[11–13]. Several drugs shown to be more or less eﬀective in
atherosclerotic disease are in the recent experiments, at the
same time eﬀective against C. pneumoniae. Statins, aspirin,
and dietary polyphenolic compounds are among them. It is
possible that the truly eﬀective treatment targeting chronic
C. pneumoniae infection will be found. At the same time,
the development of eﬃcacious vaccine should be contin-
ued [136]. The interpretation of the fact that astrocytes,
microglia, and neurons are host cells for C. pneumoniae in
the brain of AD patients, and that infected cells can be found
in close proximity to both NSP and NFT, is hampered by the
fact that most studies were done with diﬀerent diagnostic
methods, none of which still standardized. This has led
a wide variation of interlaboratory test performance, even
when the same test and the same criteria have been used.
Thus, the actual involvement of C. pneumoniae in AD still
remains a matter of debate and requires further under-
standing through standardized cultural, molecular protocols
for C. pneumoniae in autoptic samples coming from AD
patients and controls [51–53, 70]. The recent molecular,
ultrastructural, and cultural advances that have provided
evidence that C. pneumoniae is viable and metabolically
active in diﬀerent biological compartments such as CSF and
PBMC from MS patients compared to controls, suggests an
association between this pathogen and the disease, partic-
ularly in a subgroup of RR MS patients with clinical and
MRI disease activity who experience the early inﬂammatory
phase representing the development of the disease [89, 95,
108, 109]. However, the growing body of evidence suggests
ar o l eo fC. pneumoniae only as a CNS innocent bystanderInterdisciplinary Perspectives on Infectious Diseases 13
epiphenomenon due to ongoing MS inﬂammation or a
cofactor in development and progression of the disease by
enhancingapre-existingautoimmuneresponseinasubsetof
MS patients, as supported by the recent immunological and
molecularﬁndings[95,96,109].EitherforADorMSthereis
urgency for further well-designed studies to determine both
the importance of C. pneumoniae involvement in human
diseases and the usefulness of antibiotic treatment. The role
of Chlamydia in the pathogenesis of mental or neurobe-
havioral disorders including schizophrenia and autism is
uncertainandfragmentary.However,thefewexistingreports
suggest a potential involvement which will require further
conﬁrmation.
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